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Abstract
Postoperative residual muscle paralysis can lead to very serious complications, such as
hypoxia, airway obstruction, and generalized muscle weakness after surgical procedures.
Traditional anesthesia practice has utilized a class of medications called cholinesterase
inhibitors to mitigate these complications. Cholinesterase inhibiting agents have the
potential to create adverse effects of their own, such as bradycardia, due to the drug
class’s indirect mechanism of action. An ideal reversal agent would reverse quickly, and
reliably, with minimal adverse effects. Recently, sugammadex, a selective relaxantbinding agent, has been introduced as an alternative reversal agent. The purpose of this
systemic review was to compare the administration of sugammadex versus neostigmine
and time to re-establish normal muscular function, as evidenced by a train-of-four (TOF)
ratio of 0.9. Databases were searched for pertinent randomized control trials and
literature regarding the topic of this review. Inclusion and exclusion criteria were utilized
to finalize the five studies that were included in this systematic review. The PRISMA
checklist and CASP tool was utilized to extract and critically appraise each study.
Additionally, a cross study analysis was performed. Overall, sugammadex was found to
be a faster and more reliable reversal agent, with mild-to-moderate adverse effects
reported, when compared to the anticholinesterase, neostigmine. Consistently and
reliably reversing neuromuscular blocking agents and educating other health care
professionals about the negative consequences of postoperative residual muscle paralysis,
are initiatives that the advance practice nurse, particularly the CRNA, can lead.
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A Systematic Review Comparing Neostigmine Versus Sugammadex For Reversal of
Rocuronium-Induced Neuromuscular Blockade
Background/Statement of the Problem
Muscle relaxation induced by neuromuscular blocking agents (NMBAs) has been
commonly used in anesthesia practice to enable paralysis. NMBAs facilitate tracheal
intubation by paralyzing the vocal cords, allowing an endotracheal tube to pass without
causing laryngeal trauma. Additionally, the paralysis induced by NMBAs during surgery
assists to optimize surgical conditions by relaxing the skeletal musculature, inhibiting
reflexive movement to noxious surgical stimuli, and inhibiting spontaneous ventilation
(Kirkland, 2013).
In the United States, routine practice of reversing non-depolarizing NMBAs
varies amongst anesthesia providers. The potential for residual paralysis caused by an
incomplete non-depolarizing NMBA reversal could negatively impact patients in the
post-operative period. Post-operative residual paralysis (PORP), defined as muscle
weakness due to incomplete or absent antagonism of non-depolarizing neuromuscular
blockers, has been shown to increase morbidity and mortality (Mathias & Bernardis,
2012). Mathias and Bernardis (2012) identified complications of residual paralysis to
include: increased risk of regurgitation due to weakness in the hypoglossal and
esophageal sphincter muscles, hypoxia, airway obstruction, generalized muscle
weakness, and difficulty speaking or drinking. The primary prevention strategy for
PORP and subsequent complications has been pharmacologic reversal, which ensures
safety and termination of the NMBA effect (Kirkland, 2013).
Anesthesia practice has traditionally reversed neuromuscular blockade with a
cholinesterase inhibitor, neostigmine, administered concurrently with an anticholinergic
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agent, such as atropine or glycopyrrolate. Cholinesterase inhibitors work indirectly,
increasing the amount of acetylcholine available within the neuromuscular junction
(NMJ), to compete for binding sites on the muscle’s nicotinic acetylcholine receptor
(Welliver, 2013). Limitations and adverse effects exist with the use of cholinesterase
inhibitors due to the drug’s indirect mechanism of action. Adverse effects of
cholinesterase inhibitors result from excess acetylcholine and include: bradycardia,
increased gastric motility, airway secretions, bronchoconstriction, and arrhythmias
(Nagelhout, 2013). An anticholinergic agent administered concurrently with
cholinesterase inhibitors has traditionally been used to blunt the degree of adverse effects.
One of the main limitations of using cholinesterase inhibitors has been the inability to
produce a consistent and reliable train-of-four (TOF) ratio of 0.9 within 30 minutes
(Nagelhout, 2013). TOF, a method of nerve stimulation, utilizes a peripheral nerve
stimulator (PNS) to deliver four electrical impulses every 0.5 seconds at a frequency of
two hertz for a total of two seconds, to determine depth of neuromuscular blockade
(Nagelhout & Plaus, 2014). Each of the four impulses causes a muscle twitch, referred to
as T1 through T4. The TOF ratio uses an accelerometer to quantitatively compare the last
twitch, T4, to the first twitch, T1, to yield a numeric ratio.
The varying degree of effectiveness and unpleasant side effects of cholinesterase
inhibitors led to the investigation of alternative reversal agents. Ideally, a reversal agent
would provide a rapid onset, produce minimal adverse effects, and re-establish muscle
function reliably and consistently, regardless of neuromuscular blockade depth
(Nagelhout, 2013).
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Sugammadex, a reversal agent specific for the aminosteroid class of nondepolarizing NMBAs, was initially studied with the intent that the compound would
increase the solubility of the NMBA, rocuronium, in specific media. However, while
under investigation, sugammadex was observed to permanently bind with the rocuronium
molecule (Welliver, 2013). The irreversible bond of sugammadex and rocuronium
created a stable and inactive complex that was eliminated by the kidneys. Clinical trials
have shown sugammadex to be exponentially faster in reversing rocuronium-induced
block, when compared to neostigmine, due to the direct mechanism of action (Welliver,
2013).
Therefore, the purpose of this paper was to complete a systematic review to
compare the administration of sugammadex versus neostigmine and time to re-establish
normal muscular function, as evidenced by a TOF ratio of 0.9.
Next, a review of the literature will be presented.
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Literature Review
The primary databases searched were CINHAL Plus with full text, PubMed, and
the Cochrane Library. The key words used in the literature search were neuromuscular
blockade, sugammadex, neostigmine, and rocuronium. The key words were searched
separately and combined to generate results over a period of ten years, from 2008- 2018.
Neuromuscular Junction Anatomy & Physiology
The nerves of the peripheral nervous system regulate skeletal muscle contraction
and relaxation. The anatomical region where the nerve and skeletal muscle synapse is
referred to as the neuromuscular junction (NMJ). The NMJ is comprised of three major
structural components: the pre-synaptic nerve, synaptic cleft, and the postsynaptic muscle
membrane. Acetylcholine (ACh) is the chemical transmitter that is responsible for
communication between the pre-synaptic nerve and the postsynaptic muscle membrane.
An action potential causes depolarization of the pre-synaptic nerve, releasing ACh
molecules into the synaptic cleft. ACh diffuses across the cleft to the postsynaptic
muscle membrane, specifically the motor end plate, where it binds to the muscle’s
nicotinic acetylcholine receptor (nAChR) (Plummer-Roberts, Trost, Collins, & Hewer,
2016).
The muscle’s nAChR is a complex composed of five subunits: two alpha (a)
subunits, and one of each: beta (b), delta (d), and epsilon (e) subunits. These subunits are
organized cylindrically to form a transmembrane channel. When ACh occupies each of
the a-subunits, the nAChR undergoes a conformational change opening the channel,
allowing sodium and calcium influx, and potassium efflux in the skeletal muscle
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(Plummer-Roberts et al., 2016). Sodium entry into the skeletal muscle activates the
muscle’s sarcoplasmic reticulum to release calcium and induce skeletal muscle
contraction.
Acetylcholinesterase is an enzyme that is present at the motor end plate of the
skeletal muscle membrane. Once ACh is inactivated by acetylcholinesterase at the
nAChR, skeletal muscle relaxation ensues. This enzyme hydrolyzes ACh into its inactive
constituents: acetate and choline. Acetate and choline constituents are recycled to
synthesize subsequent ACh molecules to allow for ensuing skeletal muscle contraction
(Plummer-Roberts et al., 2016).
Neuromuscular Blockade
Neuromuscular blockade, also referred to as muscle relaxation, occurs when
transmission of the nerve impulse at the NMJ is blocked, inhibiting skeletal muscle
contraction. NMBAs exert their effect by altering the ability of the chemical transmitter
ACh to bind to the muscle membrane’s nAChR. There are two classes of NMBAs that
can be used to accomplish muscle relaxation: depolarizing agents and non-depolarizing
agents (Kirkland, 2013).
Use of an NMBA may be required to facilitate tracheal intubation or inhibit
spontaneous, reflexive movements to safely complete an operation. The depth and length
of muscle relaxation required is dependent on the surgical procedure performed. For
example, if skeletal muscle tone is to affect operating conditions and surgical outcomes,
then muscle relaxation with the use of NMBAs would be beneficial (Kirkland, 2013).
One commonly cited surgical procedure requiring muscle relaxation is laparoscopic
surgery in an area near the patient’s diaphragm. Cited benefits of paralysis for this type
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of procedure include: immobility, enhanced vision, and improved access to the surgical
field (Kirkland, 2013).
Non-depolarizing agents. Non-depolarizing NMBA’s work by competitively
binding one of the two a-subunits on the muscle’s nAChR, a mechanism referred to as
“antagonizing”. Blockade of one a-subunit on the nAChR, prevents the neurotransmitter
ACh from binding the required two a-subunits to induce skeletal muscle contraction.
This mechanism prevents depolarization at the skeletal muscle’s motor end plate,
resulting in muscle paralysis (Plummer-Roberts et al., 2016).
Non-depolarizing agents are further classified into two categories:
benzylisoquinoline and aminosteroid compounds. The major difference between these
drug categories is their pharmacokinetic profile. Benzylisoquinoline blocking agents are
eliminated by Hoffmann elimination, which relies on body temperature and pH to
metabolize and eliminate the agents. Aminosteroid blocking agents rely on hepatic and
renal systems for metabolism and elimination. Benzylisoquinoline blocking agents may
be preferred in patients with liver or renal dysfunction, while aminosteroid blocking
agents may be preferential in asthmatic patients due to the lack of histamine release.
Commonly used agents in the aminosteroid class of NMBA’s include: pancuronium,
rocuronium, and vecuronium (Papathanas & Killian, 2017).
Residual Neuromuscular Blockade
The presence of skeletal muscle weakness after administration of a neuromuscular
blocking agent is referred to as residual neuromuscular blockade (RNMB). Wiatrowski,
Martini, Flanagan, Freeman, and Sloan (2018) identified that RNMB occurs
postoperatively in 20-60% of patients who receive non-depolarizing NMBAs. The
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sequelae that result from RNMB include airway obstruction, impaired oxygenation and
ventilation, hypoxemia resulting in the need for re-intubation, as well as the risk for
aspiration due to impaired pharyngeal reflexes (Wiatroswki et al., 2018). These
complications are serious, potentially life-threatening, and increase patient perioperative
morbidity and mortality.
Measures of monitoring neuromuscular blockade
Administration of NMBAs requires vigilant assessment and observation by the
anesthesia provider. The practice standard set forth by the American Association of
Nurse Anesthetists (AANA) requires monitoring of neuromuscular response to NMBAs,
assessment of the depth of blockade and assessment of skeletal muscle recovery (AANA,
2013). An excessive dose of a NMBA may cause residual skeletal muscle paralysis postprocedure, while an inadequate dose may result in unanticipated movement during
critical portions of a surgical procedure (Nagelhout & Plaus, 2014).
Experts endorse routine monitoring of neuromuscular blockade as a cornerstone
of patient safety. Monitoring neuromuscular blockade intraoperatively helps guide the
anesthesia provider in determining the depth of muscle relaxation, while avoiding overparalysis and resulting post-operative residual paralysis (Nagelhout & Plaus, 2014).
Anesthesia providers use a combination of clinical, qualitative, and quantitative measures
to determine recovery from neuromuscular blockade.
Qualitative measures. Qualitative monitoring is a form of subjective monitoring,
which allows the anesthesia provider to assess the degree of blockade by a visual and/or
tactile response to a stimulus. Qualitative measures are commonly assessed by direct
clinical tests or use of an electrical stimulus from a peripheral nerve stimulator (PNS)
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(Mathias & Bernardis, 2012). A peripheral nerve stimulator device can deliver various
patterns of electrical impulses to a patient’s nerve through skin electrodes to evoke a
predictable muscle contraction (Nagelhout & Plaus, 2014). Common neuromuscular
monitoring tests that are used to produce a predictable, visible pattern of muscle
contraction include: single twitch, train-of-four, double-burst simulation, tetanus, and
post-tetanic count (Appendix A).
Train-of-four (TOF) monitoring. TOF monitoring exerts a series of four separate
electrical impulses 0.5 seconds apart at a frequency of two hertz (Hz) for two seconds.
This stimulus produces four observable muscle twitches, which are referred to as T1
through T4, respectively (Nagelhout & Plaus, 2014). Administration of a nondepolarizing NMBA will result in progressive diminution of the twitch response to the
electrical stimulus, a concept known as fade. The fourth twitch (T4) will disappear first,
as the neuromuscular block deepens there will be disappearance of the preceding
twitches; T3, T2, and T1, respectively. Twitches cannot be elicited when 100% paralysis
is achieved (Nagelhout & Plaus, 2014).
Of importance to the anesthesia provider is the comparison of the last twitch (T4)
to the first twitch (T1). Subjectively comparing T4 and T1 allows a determination of a
train-of-four ratio (TOFR), which assists the provider in determining the level of
neuromuscular blockade present. A TOFR of 0.9 or greater is the accepted standard to
determine adequate reversal from neuromuscular blockade, indicating that the fourth
twitch (T4) response is 90% of the first twitch (T1). Qualitatively measuring TOF may
result in inter-rater variance and a reliable TOFR of 0.9 may not always be achieved
(Wiatrowski et al., 2018).
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Clinical Tests. Clinical tests are subjective measurements of patient strength to
determine whether RNMB is evident. For example, the 5-second head lift test instructs
the patient to lift their head from a pillow for a consecutive five seconds. Recent data
supports a patient can adequately complete this task despite a TOFR of 0.45-0.75
(Wiatrowksi et al., 2018). Another traditionally used clinical test is forced vital capacity
(FVC), which is the maximum amount of air a person can exhale after a maximum
inhalation. A person with a TOFR of 0.5 can adequately complete a forced vital capacity
breath (Wiatrowski et al., 2018). The use of clinical tests to determine presence of
neuromuscular blockade is not adequate to reliably ascertain a TORF of 0.9 (Wiatrowski
et al. 2018).
Quantitative measures. Quantitative monitoring allows an objective assessment
to be made by the anesthesia provider. Quantitative monitoring utilizes the same patterns
of stimulation from a PNS and furthermore, couples the stimulus to a displacement
transducer. The displacement transducer acts as a movement measuring device and
computes a numerical value. Quantitative monitoring can be accomplished by using
acceleromyography (AMG), electromyography (EMG), mechanomyography (MMG),
and kinemyography (KMG) (Nagelhout & Plaus, 2014). Mechanomyography measures
the force of isometric contraction of a muscle after nerve stimulation. Data analyzed
from MMG devices assisted in the development of the gold standard TOFR of 0.9 to
indicate adequate return of neuromuscular function; however, due to the cumbersome setup of MMG devices their use outside of research is minimal (Wiatrowski et al., 2018).
In clinical practice, AMG devices are commonly used. AMG measures isotonic
contraction of muscle tissue in response to nerve stimulation, specifically a TOF
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stimulation pattern at the level of the ulnar nerve (Wiatrowski et al., 2018). The ulnar
nerve innervates the adductor pollicis muscle of the thumb, and when stimulated causes
the thumb to adduct. This site is best for measuring recovery from neuromuscular
blockade due to the pharmacodynamics of NMBAs and easy accessibility to providers.
Coupling this stimulation to a displacement transducer allows an output to be computed
to reflect an objective measure of the TOFR, and ascertainment of a TOFR of 0.9.
Reversal Agents
The risk of residual neuromuscular blockade and resulting skeletal muscle
weakness drives the practice for administering reversal agents. The ideal reversal agent
would provide rapid, complete, and reliable reversal with minimal side effects (Welliver,
2013). Traditionally, a class of medications called anticholinesterases have been used to
reverse neuromuscular blockade. Anticholinesterase agents require a small degree of
spontaneous skeletal muscle recovery to be efficacious in antagonizing muscle paralysis.
Although commonly used in practice, anticholinesterase agents are not without side
effects. Co-administration of anticholinergics are used to reverse these untoward effects
of anticholinesterases (Nagelhout, 2013).
Research over the last decade has introduced a new class of medications, selective
relaxant-binding agents (SRBAs), for reversal of neuromuscular blockade. Sugammadex,
a SRBA, has shown to be efficacious in reversing neuromuscular blockade regardless of
depth of paralysis with minimal adverse effects. Clinical trials have suggested that time
to a TORF of 0.9 is decreased by using sugammadex as a reversal agent (Welliver, 2013).
Anticholinesterases. Anticholinesterases are a class of medications that work to
increase the amount of ACh available at the NMJ through blockade of the enzyme
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acetylcholinesterase. Allowing ACh to accumulate increases the probability that it will
preferentially bind to the a-subunits on the nAChR, initiating skeletal muscle recovery
(Plummer-Roberts et al., 2016). The mechanism in which anticholinesterases exert their
effect is primarily through antagonism of residual non-depolarizing NMBA molecules.
Neostigmine is a commonly used anticholinesterase agent for reversal of neuromuscular
block.
Despite neostigmine’s mechanism of action, if the NMJ is highly concentrated by
the NMBA, increasing ACh molecules may be inadequate to antagonize the NMBA
(Jones, Caldwell, Brull, & Soto, 2008). Anticholinesterase agents are efficacious only
when a small degree of endogenous skeletal muscle recovery is present, therefore prudent
TOF monitoring by the anesthetist is warranted to assess for twitch responses. If 100%
blockade is present at the NMJ, neostigmine is an ineffective antagonist; and may
subsequently result in paradoxical muscle weakness if additional doses are administered
when 100% of acetylcholinesterase is inhibited (Plummer-Roberts et al., 2016).
ACh is the primary chemical messenger in the parasympathetic nervous system.
In addition to activating the nAChR in the NMJ, ACh can stimulate muscarinic receptors
throughout the body. Activating muscarinic receptors induces effects such as:
bradycardia, bronchoconstriction, increased airway secretions, and increased gastric
motility (Nagelhout, 2013). To prevent the previously stated effects, an anticholinergic
medication is administered concurrently to block activation of muscarinic receptors.
Anticholinergic medications are not without side effects, which may include: blurred
vision, dry mouth, urinary retention, and tachycardia (Nagelhout, 2013). A commonly
administered anticholinergic agent is glycopyrrolate.
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Pairing of neostigmine and glycopyrrolate is used in clinical anesthesia to reverse
neuromuscular blockade. The pairing of neostigmine and glycopyrrolate is preferential
as the two agents have a similar onset and duration of action. One of the main limitations
of this traditional method of reversal is that the time to reliably produce a TOFR of 0.9
within 30 minutes varies (Welliver, 2013).
Selective relaxant-binding agents. Sugammadex is the only available selective
relaxant-binding agent. The structure of sugammadex is a modified g-cyclodextrin,
resembling the shape of a hollowed cone. The exterior of the cone is hydrophilic, and the
interior is hydrophobic. Hydrophobic interactions within the cone allow the steroidal
NMBAs (rocuronium, vecuronium, and pancuronium) to be encapsulated by
sugammadex in a 1:1 ratio. The rocuronium-sugammadex complex has the highest
association rate and does not easily dissociate; for every 30 million complexes formed,
only one complex dissociates (Naguib, 2015). By encapsulating the steroidal NMBAs,
sugammadex leaves them unable to antagonize the nAChR (Plummer-Roberts et al.,
2016).
The mechanism sugammadex uses to encapsulate the rocuronium molecule is
independent of enzyme systems and receptors in the body; therefore, sugammadex does
not require co-administration of other pharmacologic agents (Naguib, 2015). Due to the
high affinity of sugammadex and rocuronium, clinical studies have shown that reversal of
profound rocuronium-induced neuromuscular blockade is possible despite the lack of
endogenous muscle recovery (Naguib, 2015). The advantages of sugammadex include:
reversal of any level of blockade within 3 minutes of administration when dosed
appropriately, and lack of muscarinic side effects (Plummer-Roberts et al., 2016).
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Studies Evaluating Blockade Reversal
Acceleromyography using a train-of-four (TOF) mode of stimulation is a
consistent method of measurement of neuromuscular blockade across randomized control
trials. TOF stimulation generates four electrical impulses over 2 seconds, which evokes
muscle twitching. The mechanism of acceleromyography converts the measured
accelerations into electrical signals (Kirkland, 2013). The number, height, and
acceleration of the four muscle twitches is recorded. Prior to administering any NMBA,
the four twitches should be of equal height, yielding a TOFR of 1.0. Non-depolarizing
NMBAs cause twitch height to fade as block depth increases, which decreases the TOFR
(Kirkland, 2013). A TOFR of 0.9 is considered the gold standard of adequate reversal of
neuromuscular block.
General surgical procedures. Jones et al. (2008) conducted a phase III,
multicenter, randomized control trial in the United States, comparing the use of
sugammadex versus neostigmine for reversal of profound rocuronium-induced
neuromuscular blockade. This study included a sample size of 74 participants, American
Society of Anesthesiologists (ASA) class I-IV, at least 18 years of age, undergoing an
elective surgical procedure under general anesthesia in the supine position. Participants
were randomized to receive either 4.0mg/kg sugammadex (n=37), or 0.7mg/kg
neostigmine plus 0.014mg/kg glycopyrrolate (n=37).
After induction of general anesthesia, baseline neuromuscular function was
established using acceleromyography. Subsequently, participants received 0.6mg/kg of
rocuronium for tracheal intubation and maintenance doses of 0.15mg/kg rocuronium as
required by the surgical procedure. When surgical conditions permitted, participants
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were allowed to spontaneously recover until 1-2 post-tetanic counts (PTCs) were present,
indicating presence of profound neuromuscular blockade (Reference Appendix A). At 12 PTCs a single dose of 4.0mg/kg sugammadex or 0.7mg/kg neostigmine plus
0.014mg/kg glycopyrrolate was administered. Neuromuscular monitoring via
acceleromyography was maintained on each participant throughout the trial until a TOFR
of 0.9 was re-established (Jones et al., 2008).
Participants were assessed every 15 minutes after tracheal extubation until
discharge from the post-anesthesia care unit (PACU). A blinded assessor conducted
assessments including: level of consciousness, a 5 second head-lift, and general muscle
weakness via a rating scale of 1[extreme impairment] to 9 [no impairment], while
monitoring for potential clinical signs of residual neuromuscular blockade (Jones et al.,
2008). Participants who received sugammadex recovered to a TOFR of 0.9 within a
geometric mean time of 2.9 minutes versus 50.4 minutes in participants who received
neostigmine plus glycopyrrolate (P< 0.0001). Jones et al. (2008) concluded that
profound rocuronium-induced neuromuscular blockade could be more reliably and
rapidly reversed by sugammadex than neostigmine.
Blobner et al. (2010) conducted a quantitative, experimental, randomized control
trial in Europe, comparing the efficacy of sugammadex and neostigmine for reversal of
rocuronium-induced neuromuscular blockade. A sample size of 98 participants, at least
18 years of age, undergoing an elective surgical procedure were categorized into the ASA
class I-III. Participants were randomized into either the interventional group, which
received sugammadex (n=49), or control group, which received neostigmine (n=49).
When the participants did not require neuromuscular blocking agents any longer, they
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were allowed to spontaneously recover until the appearance of a second twitch (T2) on
TOF stimulation. At T2 the dose of assigned medications was delivered: 2.0mg/kg of
sugammadex or 50mcg/kg of neostigmine (with 10mcg/kg of glycopyrrolate). In all
participants, neuromuscular monitoring continued until recovery of the TOFR returned to
0.9. Upon arrival to the PACU, assessments were conducted of general muscle
weakness, level of consciousness, and a 5 second head-lift test. Within five minutes of
administration of the reversal agent, 98% of sugammadex patients had recovered to a
TOFR of 0.9, compared with 11% of neostigmine patients (P <0.0001). In the
neostigmine group, 101 minutes elapsed, before 98% of participants recovered to a TOFR
of 0.9. In this experimental study, drug related adverse effects were considered mild to
moderate, and there were no participants eliminated from the trial due to an adverse
event.
Bariatric surgical procedures. Gaszynski, Szewczyk, and Gaszynski (2011)
conducted a quantitative, prospective, experimental, randomized study comparing
sugammadex and neostigmine for reversal of rocuronium-induced muscle relaxation in
morbidly obese patients undergoing elective bariatric surgery. Pharmacologic alterations,
specifically, delayed drug onset and peak of action, in most anesthetic drugs are observed
in morbidly obese patients’ due to a greater volume of distribution. The intent was to
decrease time to recovery of neuromuscular function, measured by a TOF ratio of 0.9,
and prevent PORP complications. Gaszynski et al. (2011) calculated the dose of the
reversal agent in their study by using patient’s corrected body weight (CBW), instead of
patient’s ideal body weight. This calculation increased the amount of each reversal agent
each patient received. Seventy patients were randomized into either a sugammadex
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intervention group (n=35) or neostigmine control group (n=35). The sugammadex group
received 2mg/kg of CBW, and the neostigmine group received 0.05mg/kg of CBW with
concurrent administration of atropine 0.02mg/kg of CBW.
At the end of surgery, when accelerometry TOF stimulation exhibited two
twitches, study drugs were administered, and time was recorded. The mean time to
neuromuscular recovery, as evidenced by a TOFR 0.9, was two minutes in the
sugammadex group and nine minutes in the neostigmine group. Ultimately, mean time to
TOFR 0.9 was 3.5 times shorter in the sugammadex than the neostigmine group
(Gaszynski et al., 2011). Statistical t-tests identified a p value of <0.05 as a significant
finding. There was a statistically significant difference in recovery to reestablish
muscular function between sugammadex and neostigmine (p<0.05). One episode of
profound bradycardia was assessed in the neostigmine group after administration of the
study drug (Gaszynski et al., 2011). This adverse effect could have been due to using
CBW instead of ideal body weight.
Alsaeed,et al. (2017) conducted a prospective randomized trial in Saudi Arabia
comparing reversal of rocuronium blockade with sugammadex 2mg/kg of CBW versus
two different dosages of neostigmine, 2.5mg and 5mg. A sample size of 110 participants
with a body mass index (BMI) >40, undergoing elective gastric sleeve (bariatric) surgery
with general anesthesia were enrolled in this study. All participants were monitored
intraoperatively with neuromuscular transmission monitoring (NMT). Randomization of
participants into one of three groups was accomplished by use of sealed envelopes and a
randomization table. At the completion of surgery PTCs and TOF count were recorded.
The TOF count recorded immediately prior to the injection of the reversal agent in
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Groups A, B, and C, was 2 twitches, 1 twitch, and 1 twitch, respectively. Subsequently,
Group A (n=38) received sugammadex 2mg/kg of CBW, Group B (n=41) received
neostigmine 2.5mg, Group C (n=31) received neostigmine 5mg.
A timer was used to record the seconds until a TOFR of 0.9 was achieved. Group
A achieved a TOFR of 0.9 in 210 seconds, Group B in 610 seconds, and Group C in 654
seconds (Alsaeed et al., 2017). Of note, the mean values for the BMI in each Group, A,
B, and C, was 38, 46, and 46, respectively. Alsaeed et al. (2017) determined the time to
reach a TOFR of 0.9 was significantly decreased in Group A versus Groups B and C (P
<0.05), and therefore concluded that sugammadex reverses neuromuscular blockade
induced by rocuronium more rapidly than neostigmine.
Laparoscopic surgical procedures. Laparoscopic surgical procedures often
require deep neuromuscular blockade until the end of an operation. Geldner et al. (2012)
conducted a study to compare recovery from different depths of rocuronium-induced
neuromuscular blockade. Sugammadex was given during deep neuromuscular blockade,
versus neostigmine administration at the reappearance of moderate blockade in patients
undergoing laparoscopic surgery (Geldner et al., 2012).
Geldner et al. (2012) utilized a multicenter, quantitative, randomized, blinded,
control trial in their research. Ten study sites were enrolled: three in Russia; four in
Germany; two in Finland; and one in the UK. A total of 140 participants enrolled in the
study were randomized to receive either 4mg/kg of sugammadex to reverse deep
neuromuscular blockade (n=70) or 50mcg/kg of neostigmine, plus atropine 10mcg/kg
(n=70) to reverse moderate neuromuscular blockade. The efficacy variable was the
elapsed time from reversal agent administration to recovery of the TOF ratio to 0.9.
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Patients who received sugammadex recovered 3.4 times faster than patients who
received neostigmine despite the differences in depth of neuromuscular blockade;
recovery times of 2.4 minutes and 8.4 minutes, respectively. Times recorded from last
dose of rocuronium to recovery were 13.3 minutes in the sugammadex group and 35.2
minutes in the neostigmine group (Geldner et al., 2012). Documentation of the last dose
of rocuronium eliminated administration as being a confounding variable of causality
between sugammadex and neostigmine time to reversal. ANOVA bivariate statistical
analysis was utilized to determine statistical significances between the control and
intervention group. Recovery times were statistically significant in supporting the time to
reestablish neuromuscular function was decreased when sugammadex was administered
for NMBA reversal (Geldner et al., 2012).
Next, the theoretical framework utilized for this systematic review will be
discussed.
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Theoretical Framework
Systematic reviews and meta-analyses have become increasingly prevalent in
health care due to their ability to compile important data which influences clinical
practice guidelines and decision-making (Moher, Liberati, Tetzlaff, Altman, & PRISMA
Group, 2009). Critical content analysis and quality reporting of systematic reviews has
been imperative due to the paramount influence systematic reviews have on clinical
practice. To improve the quality reporting of systematic reviews, Moher et al. (2009)
developed the Preferred Reporting Items for Systematic review and Meta-Analyses
(PRISMA) statement, which allows the reader full transparency to assess the strengths
and weaknesses of any systematic review. The PRISMA statement and Critical
Appraisal Skills Programme (CASP) critical appraisal tool will be utilized to guide this
systematic review.
The PRISMA statement consists of an explicit 27-item checklist (Appendix B),
comprised of seven domains, which include: title, abstract, introduction, methods, results,
discussion, and funding (Moher et al., 2009). The checklist sets forth the minimum set of
criteria required for evidence-based research studies included in a systematic review
(Moher et al., 2009). The PRISMA checklist ensured completeness of extracted data
from each of the included randomized control trials.
The PRISMA statement also included a four-phase flow diagram (Appendix C),
which was utilized to exhibit the selection process for study inclusion and exclusion in
this systematic review. The product of the flow diagram provided a final number of
eligible studies for inclusion. Together, the PRISMA checklist and flow diagram
provided the framework for development of this systematic review.
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The critical appraisal tool employed to evaluate the studies in this systematic
review was the 11-question assessment tool from the CASP of the Centre for EvidenceBased Medicine (Polit & Beck, 2017). The first two questions of this appraisal tool
screened whether the study being critically appraised possessed enough validity to
continue reviewing (CASP, 2017). The subsequent questions stimulated systematic
evaluation of the research. Additionally, each subsequent question provided prompts,
designed to reinforce the importance of the question as it related to the research article
(CASP, 2017). Once the studies proved to have valid results and relevance, the CASP
tool provided an approach to critically appraise and conclude the usefulness of the
findings (CASP, 2017).
The CASP tool assisted to determine the trustworthiness, results, and relevance of
the research studies (CASP, 2017). The CASP tool, comprised of 11 questions, was
answered by the researcher as “yes”, “no”, or “can’t tell”. The CASP tool examined: the
validity of results, random assignment of participants, participant trajectory through the
research project, “blinding” of treatments to assessors and participants, equal assortment
and treatment, results and significance of the treatment effect, and benefit/risk ratio of the
treatment (CASP, 2017) (Appendix E).
Next, the method section will be presented and discussed.
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Method
Purpose
The purpose of this paper was to complete a systematic review to compare the
administration of sugammadex versus neostigmine and time to reestablish normal
muscular function, as evidenced by a TOF ratio of 0.9. The research question
investigated was: Is there a difference in time to re-establish normal muscular function, as
evidenced by a TOFR of 0.9, when sugammadex versus neostigmine is administered?
Inclusion/Exclusion Criteria
Inclusion criteria consisted of randomized control trials conducted within the last
ten years which included the following: adult surgical population (18 years of age or
older); American Society of Anesthesiologist (ASA) Class I-IV patients; elective surgical
procedures; use of rocuronium for neuromuscular blockade; use of TOF measurement to
measure reversal agents; and use of sugammadex as a reversal agent and neostigmine as
the comparative agent.
Exclusion criteria included: literature over ten years old; ASA class V patients;
emergent cases; pediatric cases (less than 18 years of age); use of alternate tools to assess
return of neuromuscular function; and use of other non-depolarizing steroidal NMBA’s.
Search Strategy
The primary databases used for the literature search were PubMed, CINHAL with
full text, and the Cochrane Library. An initial search of the term “neuromuscular
blockade” was conducted in each database. The search was narrowed down further with
the terms: “neostigmine”, “sugammadex”, and “rocuronium”. The search was limited to
randomized control trials from January 2007 to June 2018. Results were filtered to
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include articles written in English and then individually reviewed to determine if the
criteria had been met for inclusion in this systematic review.
Data Collection and Synthesis
Articles were reviewed methodically, and each individual study was transferred
into two data collection tables created by this author. Data collection tables were created
and tailored to meet the focus of this systematic review. Data collected and displayed in
table 1 included: site/sample, method/design, time to TOFR of 0.9 with sugammadex, and
time to TOFR of 0.9 with neostigmine. Data collected and displayed in table 2 included:
type of elective procedure, adverse events, results, and limitations (Appendix D).
Table 1 – Data Collection Tool 1
Site/Sample

Method/Design

Time to TOFR of 0.9
with Sugammadex

Time to TOFR of 0.9
with Neostigmine

Table 2 – Data Collection Tool 2
Type of Elective Procedure

Adverse Events

Results

Limitations

Critical Appraisal Tools
Critical appraisal of research allows the investigator to evaluate the findings in a
systematic way and utilize findings to make clinical practice decisions. The CASP tool
was utilized to critically appraise the randomized control trials to determine the
credibility of the studies included in this systematic review. All 11 questions regarding
fairness, equality, and randomization of participants; measured outcomes; generalizability
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of results; and risk-benefit analysis of trials were answered for each study to reach a
comprehensive conclusion regarding the scientific integrity of the research (CASP, 2017)
(Appendix E).
Cross Analysis
After individual analysis, all randomized control trials were cross analyzed to
compare data. The cross-study analysis evaluated the similarities and differences
between the time to return to a TOFR of 0.9 when sugammadex versus neostigmine was
administered. Additionally, the type of surgical procedure was compared across studies
to determine whether the type of surgery impacted the results. The information was
recorded in the data collection table below (Table 3) (Appendix F).
Table 3 – Cross Study Analysis
Author

Time to TOFR of 0.9 with
Sugammadex

Time to TOFR of 0.9 with
Neostigmine

Type of Surgical
Procedure

The data collection, critical appraisal and cross analysis results are reported in
narrative format in this systematic review.
Dissemination of Findings
Findings from this systematic review were disseminated through a major paper
and poster presentation. The optimal audience reached was student and certified
registered nurse anesthetists, who would be able to translate these findings into clinical
practice. Future research, including cost-analysis statistics, would be warranted to
determine whether sugammadex versus neostigmine for reversal of rocuronium-induced
neuromuscular blockade is cost-effective.
Next, the results section will be discussed.
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Results
The PRIMSA flow diagram (Appendix C), as well as the inclusion and exclusion
criteria previously discussed, were utilized for selection of randomized control trials
included in this systematic review. The PRISMA flow diagram exhibited below (figure
1.) displays the breakdown of the search strategy.

Figure 1. PRISMA Flow Diagram
The original search of the term “neuromuscular blockade” yielded 202 results. Of
the 202 results, articles were screened for duplicates. Removal of duplicate research
ceded 139 results for review. The additional terms “neostigmine”, “sugammadex”, and
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“rocuronium” were searched, which yielded 44 results for review. The titles and
abstracts were evaluated for inclusion and exclusion criteria specific to this systematic
review. The final five randomized control trials that met this systematic review’s
inclusion criteria were analyzed accordingly. Key information was extracted and
recorded into the data collection tables in Appendix D. Additionally, the studies were
critically appraised using the CASP checklist (Appendix E). The following information
summarized the results obtained from the data collection tables.
The randomized control trial conducted by Wu et al. (2014) (Appendix D1)
demonstrated efficacy between sugammadex 2mg/kg vs. neostigmine 50mcg/kg in
patients 18-64 years old of Caucasian and Chinese descent, undergoing elective surgery.
Patients were enrolled from February 2010 to September 2010 at ten various sites; six
sites in China and four sites in Europe. Subjects included for enrollment were
undergoing elective surgery with propofol anesthesia, and rocuronium for NMB.
Additionally, subjects were ASA Class I – III and never have emigrated from their birth
country. A total of 289 subjects were enrolled. The authors calculated a sample size of
115 Chinese subjects required to give a power of 95%. Due to prior studies concluding
efficacy in Caucasian subjects, the authors determined 30 Caucasian subjects per
treatment group were required to give a power of 95%. A central randomization system
was utilized to assign treatment groups; the experimental group received sugammadex
2mg/kg and the control group received neostigmine 50 mcg/kg + atropine 10-20mcg/kg.
Anesthesia was induced and maintained with IV propofol for the elective surgical
procedure. TOF baseline monitoring was recorded prior to the administration of
rocuronium. Rocuronium 0.6mg/kg was administered to facilitate tracheal intubation.
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Maintenance doses of 0.1-0.2mg/kg were administered as required throughout the
anesthetic. Toward the conclusion of surgery, at the reappearance of a T2 twitch, the
experimental group received sugammadex 2mg/kg and the control group received
neostigmine 50mcg/kg + atropine to reverse rocuronium-induced neuromuscular
blockade. Following administration of reversal agents, the time to recover a TOF ratio of
0.9 was recorded. The authors found that sugammadex 2mg/kg provided rapid reversal
of rocuronium-induced neuromuscular blockade when compared with neostigmine in
both Chinese and Caucasian subjects (p value of 0.0001). Chinese subjects who received
sugammadex recovered to a TOF ratio of 0.9 in 1.6 minutes versus 9.1 minutes in
Chinese subjects who received neostigmine. Caucasian subjects recovered to a TOF ratio
of 0.9 in 1.4 minutes and 6.7 minutes after receiving sugammadex and neostigmine,
respectively.
The study demonstrated (Appendix D1) there was a significantly faster time to
recover to a TOF ratio of 0.9 in both Chinese and Caucasian subjects who received
sugammadex 2mg/kg. Adverse events reported included: bradycardia and
hypersensitivity reactions to the reversal agents. Of the eleven reported cases of
bradycardia, ten of the cases used neostigmine, while only one Chinese subject
experienced bradycardia with sugammadex. Hypersensitivity reactions were reported in
ten Chinese subjects, seven received sugammadex, and three received neostigmine. The
authors identified that interethnic differences were likely to be multifactorial, and no
obvious limitations were reported in the study.
Critical analysis of the Wu et al. (2014) study using the CASP checklist
(Appendix E1) revealed all except two of the critical appraisal questions were scored as
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“yes”. The first question scored as “no” regarded whether patients, health workers, and
study personnel were ‘blind’ to treatment. In Wu et al. (2014), patients who consented to
study enrollment were blinded to the treatment received. The study investigators were
blinded to treatment, however, the anesthesia provider administering the drug was not
blinded. The second question scored as “no” regarded whether the groups were similar at
the start of the trial. Of the 289 subjects enrolled, 230 Chinese subjects were divided into
two treatment groups, and 59 Caucasian subjects were further divided into two treatment
groups. Gender composition of the groups was not classified by the authors, however
racial differences were purposefully categorized at the inception of this study. Aside
from these two questions, the trial clearly addressed a focused issue, randomized the
assignment of patients to treatments, and properly accounted for all patients at the study’s
conclusion. All patients enrolled in the study were treated equally.
The next randomized control trial by Woo et al. (2013) (Appendix D2) was
conducted to evaluate the efficacy of rocuronium-induced neuromuscular blockade
reversal in Korean patients when sugammadex versus neostigmine was administered as
the reversal agent. The study was a randomized, parallel-group, active-controlled, safety
assessor-blinded phase IV study, conducted at seven sites in the Republic of Korea.
Enrollees were of Korean descent, ASA class I-III, undergoing an elective surgical
procedure under general anesthesia using rocuronium for NMB. A sample size of 128
subjects undergoing elective surgery were randomized on a 1:1 basis to receive either
sugammadex 2mg/kg or neostigmine 50mcg/kg + glycopyrrolate 10mcg/kg. The authors
determined a sample size of 50 Korean subjects per treatment group would be required to
provide a power of 95%, testing at a significance level of 0.05. Anesthesia was induced
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with IV propofol and maintained with inhalational sevoflurane. Neuromuscular
monitoring was established, subsequently rocuronium 0.6mg/kg was administered to
facilitate endotracheal intubation. Maintenance doses of rocuronium 0.1- 0.2mg/kg were
administered as required throughout the anesthetic. During the conclusion of surgery, at
the appearance of a T2 twitch, a solitary dose of sugammadex 2mg/kg or neostigmine
50mcg/kg + glycopyrrolate was administered to reverse neuromuscular blockade. Time
elapsed from administration of reversal agent to recovery of a TOF ratio of 0.9 was
recorded. The authors concluded mean time to recover a TOF ratio of 0.9 was 1.8
minutes in Korean subjects who received sugammadex, and 14.8 minutes in subjects who
received neostigmine (p < 0.0001). Treatment related adverse events reported were of
mild-to-moderate intensity. Four subjects who received sugammadex had reactions that
included: bradycardia (n=1) and headache (n=3). Six subjects who received neostigmine
reported headache (n=2), nausea (n=1), recurrence of NMB (n=1), rash (n=1), and
hypotension (n=1). The authors did not report limitations of the study.
Critical appraisal of the Woo et al. (2013) study (Appendix E2) identified all
subjects were randomized into one of two treatment groups to receive either sugammadex
or neostigmine, however the specific method utilized for randomization was not disclosed
by study investigators. All questions except one, were scored as “yes” on the CASP tool.
The single question that scored “no” addressed whether patients, health workers, and
study personnel were ‘blind’ to treatment. Patients and study investigators were blinded
to treatment. The anesthesiologist administering either sugammadex or neostigmine was
not blinded, however was prohibited from revealing the assigned treatment group to
study investigators. Both treatment groups were similar at the start of the trial, and the
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trial addressed a clearly focused issue. All subjects that participated in the study were
treated equally throughout and properly accounted for at its conclusion.
In the study by Gaszynski et al. (2011) (Appendix D3), researchers evaluated the
efficacy of neostigmine versus sugammadex for reversal of rocuronium-induced muscle
relaxation. Seventy morbidly obese patients (BMI > 40) undergoing an elective bariatric
surgical procedure were included in this single center study performed at the Medical
University of Lodz, Poland. Envelopes were prepared by a study investigator and used
for participant randomization. The experimental group was composed of 35 subjects who
received sugammadex 2mg/kg of CBW and the control group comprised of 35 subjects
who received neostigmine 50 mcg/kg CBW + atropine 0.02mg/kg CBW. Both groups
were induced using IV propofol in 1.5-2mg/kg CBW doses and maintained with an
inhalational desflurane, oxygen, and air mixture. Baseline TOF monitoring was obtained,
then neuromuscular blockade was induced with rocuronium 1mg/kg of CBW to facilitate
tracheal intubation. If the TOFR spontaneously recovered to 1.0 during surgery, two
additional rocuronium doses of 0.06mg/kg CBW could be administered. At the
conclusion of surgery at the reappearance of a T2 twitch, either sugammadex 2mg/kg
CBW or neostigmine 50mcg/kg + atropine 0.02mg/kg CBW were administered based on
participant randomization. Time elapsed from administration of reversal agent to a
TOFR of 0.9 was recorded. Patients who received sugammadex recovered to a TOFR of
0.9 in a mean time of 2 minutes and 44 seconds, while patients who received neostigmine
recovered in a mean time of 9 minutes and 37 seconds. The authors reported, with
significance, that recovery to a TOFR of 0.9 was 3.5 times faster in patients who received
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sugammadex (p <0.05). Limitations of this study were the small number of participants
which has limited application to clinical outcomes.
Critical appraisal of the Gaszynski et al. (2011) study (Appendix E3), showed all
but two of the CASP questions were scored as “yes”. The trial addressed a clearly
focused issue between two similar groups. Additionally, all subjects that participated in
the study were treated equally throughout and properly accounted for at its conclusion.
The first question scored as “no” was whether patients, health workers, and study
personnel were ‘blind’ to treatment. Patients and study investigators were blinded to
treatment. The anesthesia provider administering the reversal agent was not blinded to
treatment. The second question scored as “no” regarded the precision of the estimate of
the treatment effect. The authors failed to clearly identify the sample size required to
provide and report a power analysis.
Illman et al. (2011) (Appendix D4) evaluated time to achieve a TOFR of 0.9 when
sugammadex 2mg/kg versus neostigmine 50mcg/kg was administered as the reversal
agent for rocuronium-induced neuromuscular blockade. Fifty subjects were enrolled at
two University hospitals in Finland. Subjects were 18-70 years of age, ASA Class I – IV,
undergoing elective surgery under general anesthesia. The authors identified twentythree patients were required in each treatment group to give a power of 90%, testing at a
significance level of 0.05. Exclusion criteria included significant renal, hepatic, or
ventilatory dysfunction, BMI > 32.5, pregnancy, patients with muscular dystrophies, and
patients already on medications known to interfere with neuromuscular transmission.
General anesthesia was induced according to usual practice of the study center
with IV propofol and an IV opioid. Rocuronium, 0.6-1mg/kg, was administered based on
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clinical factors, duration of surgery, and facilitation of tracheal intubation. Anesthesia
was maintained using an inhalation agent (either sevoflurane or desflurane) and opioids.
Neuromuscular monitoring was initiated using TOF stimulation. Additional rocuronium
was administered in 5-10mg doses as clinically necessary. At the conclusion of surgery,
computer-generated sealed envelopes were utilized to randomly assign patients to receive
either neostigmine 50 mcg/kg + glycopyrrolate 10 mcg/kg or sugammadex 2mg/kg. The
reversal agent was prepared by a study nurse and administered when the anesthesiologist
visualized a T2 twitch on TOF stimulation. The anesthesiologist remained blinded to the
reversal agent administered by the study nurse. The time elapsed between a T2 twitch
and recovery to a TOFR of 0.9 was recorded by study investigators. Mean time to
achieve a TOFR of 0.9 after administration of sugammadex and neostigmine +
glycopyrrolate was 1.7 ± 0.7 minutes and 13.3 ± 5.7 minutes, respectively. The results
from Illman et al. (2011) concluded time to recover a TOFR of 0.9 was significantly
shorter when sugammadex 2mg/kg was administered (P < 0.001).
The results of this study support the use of sugammadex as a faster and more
reliable reversal agent than neostigmine. However, some limitations have been identified
in the Illman et al. (2011) study. The use of 2 different volatile agents and 3 different
opioids may be regarded as a limitation due to varying synergistic effects of the
anesthetic agents. Additionally, the percent of inspired volatile agent was not reported,
which could influence the degree of skeletal muscle relaxation.
Critical appraisal of this study (Appendix E4) shows all critical appraisal
questions were scored as “yes”. All participants were properly accounted for at the trial’s
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conclusion. Patients, health workers, and study personnel were blinded to the treatment.
Both groups were treated equally, and all clinically important outcomes were considered.
Blobner et al. (2010) (Appendix D5) included ninety-eight patients undergoing
elective surgery, in a randomized control trial to evaluate efficacy of sugammadex versus
neostigmine for reversal of rocuronium-induced neuromuscular blockade. This study
included thirteen sites in Europe. The authors identified that to have a power of 95%
testing at a significance level of 0.05, a total of 46 patients would have to be enrolled in
each group. Patients enrolled were at least 18 years old, ASA class I-III, undergoing
general anesthesia. Patients were excluded if they were an expected difficult intubation,
had known renal or hepatic dysfunction, or a known contraindication to the medications
used during the study.
Ninety-eight patients were randomized into two groups to receive either
sugammadex 2mg/kg or neostigmine 50mcg/kg + glycopyrrolate 10mcg/kg. Anesthesia
was induced with IV propofol, maintained with inhalational sevoflurane, and opioids
were supplemented during the anesthetic as clinically indicated. Baseline TOF
monitoring was obtained, subsequently rocuronium 0.6mg/kg was administered to
facilitate tracheal intubation and abolish successive twitch responses. Maintenance doses
of 0.1-0.2mg/kg of rocuronium were administered during the anesthetic as clinically
indicated. When neuromuscular blockade was no longer required, patients were allowed
to spontaneously recover to a T2 twitch on TOF stimulation. At the appearance of a T2
twitch, sugammadex 2mg/kg or neostigmine 50mcg/kg + glycopyrrolate 10mcg/kg was
administered. Blobner et al. (2010) concluded patients who received sugammadex
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recovered in a significantly shorter amount of time than patients who received
neostigmine (P <0.0001), 1.5 minutes and 18.6 minutes, respectively.
Critical appraisal (Appendix E5) of the Blobner et al. (2010) study revealed all
critical appraisal questions were scored as “yes” except for one that addressed whether
patients, health workers, and study personnel were ‘blind’ to treatment. The participants
were blinded to treatment, as were the study personnel. The anesthesia provider
administering the reversal agent was not blind to treatment. The relative distribution of
surgical procedures was similar, and both groups were treated equally. All participants
were properly accounted for at the study’s conclusion.
Cross Analysis
The randomized control trials included in this systematic review were cross
analyzed (Appendix F). The cross analysis of these studies compared time to establish a
TOFR of 0.9 with sugammadex, time to establish a TOFR of 0.9 with neostigmine, and
the type of elective surgical procedure which required general anesthesia.
All the randomized control trials included in this systematic review evaluated the
efficacy of sugammadex versus neostigmine for reversal of rocuronium-induced
neuromuscular blockade. All randomized control trials used general anesthesia as the
primary anesthetic. All surgeries were elective, performed on ASA class I-IV patients.
Patients with co-morbidities that could potentially affect the outcomes of the study, such
as renal or hepatic dysfunction were excluded.
Although surgical procedures varied or were not specifically identified, results
were not impacted based on the type of surgery performed. Wu et al. (2014) did not
specify the type of surgical procedure, however the authors identified that the surgery
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was elective. Woo et al. (2013) investigated patients undergoing elective operations of
the ear, nose, and larynx (48%), gynecologic (18%), digestive system and spleen (17%).
Gaszynski et al. (2011) evaluated patients undergoing elective bariatric surgery. Illman
et al. (2011) did not specify the type of elective surgical procedure. Blobner et al. (2010)
studied patients undergoing a variety of elective operations, including: ears, nose, and
larynx (19%); teeth, jaws, mouth, and pharynx (16%); digestive system and spleen
(16%); urinary system, male genital organs, and retroperitoneal space (13%);
musculoskeletal system (12%); female genital organs (9%); endocrine system (7%); eye
and adjacent structures (4%); and mammary gland surgery (2%). The cross-study
analysis results supported the hypothesis that sugammadex 2mg/kg would be a reliably
faster acting agent to reverse moderate levels of rocuronium-induced neuromuscular
blockade, when compared to neostigmine (Appendix F). Mild-to-moderate adverse
effects of both sugammadex and neostigmine were reported, however the benefits of
quickly and reliably reversing neuromuscular blockade outweighed the associated risks.
Next, the summary and conclusions section will be presented.
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Summary and Conclusion
A comprehensive understanding of the neuromuscular junction and mechanism of
action of varying muscle relaxants has been a cornerstone of modern anesthesia practice.
A thorough literature review was conducted to highlight the importance of using
neuromuscular blocking agents to facilitate safe surgical procedures, as well as the
importance of properly reversing these agents. Wiatrowski et al. (2018) identified
residual neuromuscular blockade occurs postoperatively in 20-60% of patients who
received non-depolarizing NMBAs. Detrimental consequences that could potentially
result include: aspiration from impaired reflexes, airway obstruction, and impaired
oxygenation and ventilation requiring re-intubation (Wiatrowski et al., 2018).
Assessment of neuromuscular blockade intraoperatively has been a standard of
nurse anesthesia practice (AANA, 2013). Various clinical assessments have been utilized
to determine adequate neuromuscular recovery; however, the gold standard of recovery
remains a TOF ratio of 0.9 as measured by AMG. Nagelhout (2015) identified one of the
main limitations of using cholinesterase inhibitors for reversal was the inability to
produce a consistent and reliable TOFR of 0.9 within 30 minutes. Naguib (2015) cited
advantages of sugammadex to include reversal of any level of blockade within 3 minutes
of administration, lack of muscarinic side effects, and independence of enzyme systems
and receptors in the body. Review of the literature warranted the need for this systematic
review to determine the most reliable and consistent reversal agent of moderate levels,
evidenced by a T2 twitch, of rocuronium-induced neuromuscular blockade.
The purpose of this systematic review was to assess the efficacy of neostigmine
versus sugammadex for reversal of moderate levels of rocuronium-induced
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neuromuscular blockade in adult patients undergoing an elective surgery under general
anesthesia. Pubmed, CINHAL with full text, and the Cochrane Library databases were
searched to find relevant articles. The PRISMA checklist and flow diagram was utilized
to exhibit the selection process for study inclusion.
After development of inclusion and exclusion criteria, a total of five studies were
selected as meeting criteria for inclusion in this systematic review. Each study was
thoroughly analyzed to allow extraction of pertinent data for summarization in data
collection tables. Following data extraction, the five studies were critically appraised
utilizing the CASP checklist. An analysis across studies, which focused on the type of
surgical procedure, and time to obtain a TOF ratio of 0.9 in both the control and
experimental groups was conducted.
All five studies included in this systematic review identified that sugammadex,
when compared to neostigmine, more reliably and consistently reversed moderate
rocuronium-induced neuromuscular blockade to a TOFR of 0.9. There were mild-tomoderate sugammadex-related adverse effects reported in all five studies, however, the
benefits of reliably reversing neuromuscular blockade outweighed the risk of adverse
outcomes. There were some limitations identified in this systematic review. There was
variation among dosing methods in the studies included. Wu et al. (2014) utilized actual
body weight to calculate reversal agent doses, Gaszynski et al. (2011) utilized corrected
body weight, and the remaining studies did not clearly identify the weight used to
determine doses. Three of the studies were financially supported by the pharmaceutical
company Merck Sharp & Dohme Corp, which owns and manufacturers sugammadex.
The length of the surgical procedure, timing elapsed from the last dose of rocuronium,
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and concurrently administered anesthetic doses was not identified across studies, which
could be considered a limitation. An additional limitation of this systematic review could
be that only three databases were utilized to extract randomized control trials.
In summary, the five randomized control trials included in this systematic review
supported sugammadex as reliable and consistent in producing a TOFR of 0.9, in a
significantly shorter time, when compared to neostigmine for reversal of rocuroniuminduced neuromuscular blockade.
Next, the recommendations and implications for advanced nursing practice will
be discussed.
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Recommendations and Implications for Advanced Nursing Practice
Residual neuromuscular blockade is a serious and potentially life-threatening state
that increases perioperative morbidity and mortality. Certified Registered Nurse
Anesthetists (CRNAs), advanced practice nurses, have become integral members of the
anesthesia care team. CRNAs administer more than 45 million anesthetics to patients
each year in the United States (AANA, 2019). Anesthesia administration is both an art
and science, in which emerging evidence and research must be continuously incorporated
into practice in order to achieve clinical and professional competency.
There have been many proposed methods for assessment and evaluation of
adequate neuromuscular recovery. The gold standard for adequate recovery from
neuromuscular blockade is a TOFR of 0.9 by use of AMG. The ideal reversal agent
would quickly and reliably achieve a TOFR of 0.9 without adverse effects. Traditionally,
neuromuscular blockade has been reversed with an anticholinesterase, administered
concurrently with an anticholinergic to reduce adverse effects. In recent years, selective
relaxant-binding agents have been investigated to determine efficacy and reliability in
reversing neuromuscular blockade.
Systematic reviews provide current information regarding the safest and most
effective methods of administering anesthesia. The results of this systematic review
demonstrate sugammadex can quickly and reliably reverse moderate levels of
rocuronium-induced neuromuscular blockade without serious adverse consequences. All
five studies showed faster recovery to a TOFR of 0.9 with sugammadex when compared
to neostigmine. It is important to note that mortality was not increased in any cohorts
studied.
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Further research on patient populations beyond the scope of this systematic
review should be conducted to determine the safety profile of sugammadex in these
groups. Furthermore, a cost analysis should be conducted to determine whether
sugammadex has a comparable cost to neostigmine administered with an anticholinergic
agent. An additional cost analysis should be conducted to determine whether reversal
with sugammadex affects the amount of operating room (OR) time utilized, and therefore
the cost of overall OR time, when compared to neostigmine.
CRNAs are uniquely positioned to provide safe patient care to a variety of
patients in the perioperative period. Administration of sugammadex has been proven to
be a faster and more reliable agent in preventing the incidence of adverse events related
to residual neuromuscular blockade induced by rocuronium. Although sugammadex and
neostigmine are both effective at reversing neuromuscular blockade, there are clinical
situations where a faster and more reliable reversal using sugammadex would be
preferred. For example, in a “cannot intubate and cannot ventilate” scenario immediately
after induction of anesthesia, or when muscle relaxation is required to the end of a
surgical procedure. Sugammadex may also be preferential in patients who cannot
tolerate significant variations in heart rate, which may be observed when an
anticholinesterase agent is utilized. These are examples of clinical situations in which the
CRNA may want to advocate for use of sugammadex. CRNAs can become actively
involved in developing appropriate treatment algorithms for use of sugammadex versus
neostigmine + glycopyrrolate within the facilities they provide anesthesia based on
current and emerging research. Additionally, CRNAs can educate colleagues on the
clinical advantages of sugammadex. The CRNA, as an advanced practice nurse, has a
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duty to provide the most effective and appropriate care to patients, while mitigating
adverse effects. Sugammadex has emerged as an appropriate and effective drug to
mitigate adverse effects of neuromuscular blockade reversal, and the CRNA should be
knowledgeable in the appropriate use of this medication.
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Appendix D
Data Extraction Tables
Table D1 – Wu, X., Oerding, H., Liu, J., Vanacker, B., Yao, S., Dahl, V., … Woo, T. (2014). Rocuronium blockade reversal with
sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC anesthesiology, 14(53). doi:10.1186/14712253-14-53
Site/Sample

Method/Design

Time to TOFR of 0.9
with Sugammadex

Time to TOFR of 0.9
with Neostigmine

Multi-center study (6
sites in China & 4 sites
in Europe)

Randomized, parallel group, multicenter, safetyassessor blinded study

1.6 minutes in Chinese
subjects

9.1 minutes in Chinese
subjects

Screening of subjects took place ≤ 7 days prior to
treatment administration. Eligible subjects were
randomized via a computerized central
randomization system in a 1:1 ratio to either
receive: sugammadex 2mg/kg or neostigmine
50mcg/kg with atropine 10-20mcg/kg

1.4 minutes in
Caucasian subjects

6.7 minutes in
Caucasian subjects

289 Subjects enrolled
in trial (230 Chinese
subjects & 59
Caucasian subjects)
Subjects aged 18-64
years
Undergoing Elective
Surgery
ASA Class ≤ 3

Anesthesia induced and maintained with IV
propofol, opioids administered according to local
practice. Rocuronium 0.6mg/kg was administered
prior to intubation. Rocuronium maintenance doses
of 0.1-0.2mg/kg were administered as required for
the anesthetic. After the last dose of rocuronium, at
the reappearance of a second twitch (T2), the
reversal agents were administered.
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Type of
Elective
Procedure
Not specified

Adverse Events

Results

Limitations

11 subjects experienced
bradycardia after study drugs: 7
Chinese subjects (1 received
sugammadex; 6 received
neostigmine) & 4 Caucasian
subjects (all 4 received
neostigmine)

Sugammadex provided more rapid
reversal of rocuronium-induced
neuromuscular blockade compared
with neostigmine in both Chinese &
Caucasian subjects

Doses of neuromuscular blocking
agents were based on actual body
weight instead of ideal body weight

10 Chinese subjects
experienced hypersensitivity
reactions characterized by:
mild-to-moderate rash, pruritis,
facial swelling, & facial
flushing: 7 Chinese subjects
received sugammadex; 3
Chinese subjects received
neostigmine

Chinese subjects experienced a
recovery time that was 5.7 times
faster with sugammadex versus
neostigmine (p <0.0001)
Caucasian subjects experienced
recovery from rocuronium-induced
neuromuscular blockade 4.8 times
faster with sugammadex versus
neostigmine (p <0.0001)

Length of surgical procedure not
specified
Financial support provided by
Merck Sharp & Dohme Corp.
Time elapsed from last dose of
rocuronium not specified
Type of surgical procedure not
specified
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Table D2 – Woo, T., Kim, K.S., Shim, Y.H., Kim, M.K., Yoon, S.M., Lim, Y,J., … Chon, J.Y. (2013). Sugammadex versus
neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients. Korean Journal of
Anesthesiology, 65(6), 501-507. https://dx.doi.org/10.4097/kjae.2013.65.6.501
Site/Sample

Method/Design

Multi-center
study (7 sites in
the Republic of
Korea)

Randomized, parallel-group, active-controlled, safety
assessor-blinded phase IV study

Subjects were of
Korean descent born in Korea,
never emigrated
from Korea, with
a Korean home
address (n=118)
Subjects
undergoing
elective surgical
procedure

Subjects were randomized on 1:1 basis to receive either:
sugammadex 2mg/kg or neostigmine 50mcg/kg plus
glycopyrrolate 10mcg/kg for NMB reversal
Anesthesia induced with IV propofol & maintained with
sevoflurane. Opioids were administered per local practice.
Rocuronium 0.6mg/kg was administered for intubation and
was re-dosed as clinically indicated in 0.1-0.2mg/kg doses.
After the final dose of rocuronium, at the reappearance of a
T2, the reversal agents were administered.
The anesthesia provider administering the anesthesia during
the surgery was not blinded to the randomized study drug,
but was not allowed to reveal the assigned treatment group
to the safety assessor

ASA Class ≤ 3
Blinded safety assessor performed safety assessments in the
postoperative period

Time to TOFR of
0.9 with
Sugammadex
1.8 minutes
following
administration of
sugammadex
2mg/kg

Time to TOFR of 0.9
with Neostigmine
14.8 minutes
following
administration of
neostigmine
50mcg/kg
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Type of Elective Procedure

Adverse Events

Results

Limitations

Operations of the ear, nose,
& larynx (48%)

Treatment related adverse
events:

Recovery from rocuroniuminduced neuromuscular
blockade was 8.1 times faster
with sugammadex versus
neostigmine in Korean subjects
(P<0.0001)

Doses of study related drugs
was not specific regarding
whether ideal body weight or
actual body weight was used
to determine dosing

Operations of female genital
organs (18%)

-

Operations of digestive
system & spleen (17%)
-

4 subjects in
sugammadex group
(bradycardia, n=1;
headache, n=3)
6 subjects in
neostigmine group
(headache, n=2;
nausea, n=1; recurrence
NMB, n=1; rash, n=1;
hypotension, n=1)

Time elapsed from last dose
of rocuronium not specified
Length of surgical procedure
not specified
Financial support provided
by Merck Sharp & Dohme
Corp.

51

Table D3 – Gaszynski, T., Szewczyk, T., & Gaszynski, W. (2011). Randomized comparison of sugammadex and neostigmine for
reversal of rocuronium-induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia,
108(2), 236-239. doi: 10.1093/bja/aer330
Site/Sample

Method/Design

Single center
study performed
at the Medical
University of
Lodz, Poland

Prospective, randomized, safety-assessor blinded study

70 morbidly
obese subjects
(BMI > 40)
requiring general
anesthesia &
muscle relaxation
with rocuronium
Undergoing
elective bariatric
surgery

Subjects were randomized to receive either: sugammadex 2mg/kg of
corrected body weight (CBW) or neostigmine 0.05mg/kg CBW with
atropine 0.02mg/kg CBW. Envelopes previously prepared by the
investigator were used for randomization.
Both groups had anesthesia induced with propofol 1.5-2 mg/kg CBW.
Fentanyl 0.05 mg/kg CBW administered for analgesia. Anesthesia was
maintained with an air, oxygen, & desflurane mixture. Volume % of
desflurane was based on age, clinical status, & monitoring. Neuromuscular
blockade was induced using rocuronium 1 mg/kg CBW. A maximum of
two additional doses of rocuronium 0.06mg/kg CBW were given when a
TOFR reached 1.
At surgery completion and reappearance of T2 twitch, reversal agents were
administered, and time recorded.
A blinded investigator continued to monitor TOF stimulation & perform
safety assessments in the postoperative period

Time to TOFR
of 0.9 with
Sugammadex
2 minutes 44
seconds
following
administration
of sugammadex
2mg/kg CBW

Time to TOFR
of 0.9 with
Neostigmine
9 minutes 37
seconds
following
administration of
neostigmine
0.05mg/kg CBW
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Type of Elective
Procedure
Elective bariatric
surgery

Adverse Events

Results

Treatment related
adverse events
included:

Total dose of
rocuronium was
comparable between
the two groups
2 subjects in
(sugammadex
sugammadex group
group: 87.9mg;
reported “a strange taste neostigmine group:
in the mouth”
85.6mg).
3 subjects in the
negostigmine group had
significant bradycardia
that required additional
administration of
atropine

Mean time to
achieve TOFR 0.9
was 3.5 times
shorter in the
subjects who
received
sugammadex
(P<0.05)

Limitations
Investigator previously prepared envelopes for randomization,
which may increase risk for selection bias
Small sample size
ASA classification & age of participants omitted from reported
data
Use of CBW may have resulted in under-dosing in the obese
patient. Use of CBW was utilized based on recommendations
from prior authors. Manufacturer recommends dosing on actual
body weight.
Standard anesthesia practice in Poland utilizes paired use of
atropine & neostigmine; glycopyrrolate may be better paired with
neostigmine & may have altered the prevalence of adverse events
reported
Percent of inspired volatile agent not reported, higher doses may
potentiate neuromuscular blockade
Length of surgical procedure not specified
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Table D4 – Illman, H.L., Laurila, P., Antila, H., Meretoja, O., Alahuhta, S., & Olkkola, K. T. (2011). The duration of residual
neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train-of-four monitoring.
Anesthesia & Analgesia, 112(1), 63-68. doi: 10.1213/ANE.0b013e3181fdf889
Site/Sample

Method/Design

Multi-sites at
two University
Hospitals
(Oulu; Turku)
in Finland

Double-blind, randomized, multi-center study
Subject randomization into 2 groups at end of surgery, accomplished via computergenerated sealed envelopes with written instructions to prepare either: neostigmine
50 mcg/kg + glycopyrrolate 10 mcg/kg or sugammadex 2mg/kg for NMB reversal.

50 subjects
enrolled

Previous studies utilized to calculate 23 subjects would be required in each group to
gain a level of significance of P=0.05 and power of 90%.

Subjects male
& female

Anesthesia induced with propofol + opioid. Depending on clinical factors &
expected duration of surgery, rocuronium 0.6-1mg/kg (actual body weight)
administered. Anesthesia maintained with sevoflurane or desflurane and opioids.
Additional 5-10mg rocuronium administered when 2 twitch responses appeared
visually.

Subjects aged
18-70 years
Subjects BMI ≤
32.5
Undergoing
elective surgery
ASA Class ≤ 4

Degree of NMB measured with 1 monitor (acceleromyography) but two different
methods: objective monitoring & visual evaluation by the anesthesiologist. The
provider was blinded to the objective/quantified measurements.
At end of surgery, the assisting investigator administered the reversal drug when the
anesthesia provider had detected 2 visual twitch responses. Time recorded by the

Time to TOFR Time to TOFR
of 0.9 with
of 0.9 with
Sugammadex
Neostigmine
1.7 ± 0.7
13.3 ± 5.7
minutes
minutes
following
following
administration administration
of
of neostigmine
sugammadex
50mcg/kg +
2mg/kg
glycopyrrolate
10mcg/kg
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anesthesia provider when 3 and 4 twitches and no visual fade was detected after
administration of reversal. Provider remained blinded to reversal drug administered.

Type of
Elective
Procedure
Not specified

Adverse Events

Results

Limitations

1 subject experience
postoperative nausea
after receiving
neostigmine

All enrolled subjects completed the study, however 2
subjects excluded for technical failure of the
acceleromyometry device (n=1 neostigmine; n=1
sugammadex) and 1 subject excluded (n=1
neostigmine) for waking up from anesthesia before
TOFR 0.9 established.

Type of surgical procedure not
specified

No other adverse events
were reported from either
group.

Final analysis included: Neostigmine (n= 23) &
sugammadex (n=24)
Sugammadex was clinically & statistically faster in
reversing neuromuscular blockade from rocuronium (P
< 0.001)

2 different volatile agents & 3
different opioids were utilized
Length of surgical procedure
not specified.
Not specified whether doses of
reversal agents were based on
actual vs. ideal body weight
Percent of inspired volatile
agents not reported, higher
doses may potentiate
neuromuscular blockade
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Table D5 – Blobner, M., Eriksson, L.I., Scholz, J., Motsch, J., Rocca, G.D., & Prins, M.E. (2010). Reversal of rocuronium-induced
neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: Results of a randomized
controlled trial. European Journal of Anaesthesiology, 27(10). doi: 10.1097/EJA.0b013e32833d56b7
Site/Sample

Method/Design

European, 13
center study

Multi-center, randomized, parallel-group, comparative, active-controlled,
safety-assessor-blinded trial. Researched determined to have a power of 95%
to detect a difference, a minimum of 46 subjects needed to be enrolled in
each group. N=49 for each group was utilized in case subjects dropped out of
the study. Patients were randomized to receive rocuronium or vecuronium;
only the results of the subjects who received rocuronium are published in this
study. Subjects who received rocuronium were randomized to receive either:
sugammadex 2mg/kg or neostigmine 50mcg/kg + glycopyrrolate 10mcg/kg.

Age ≥ 18
years
No
restrictions
on subject
body weight
Male &
female
subjects
included
Undergoing
elective
surgery under
general
anesthesia

Anesthesia induced with propofol and maintained with sevoflurane + opioid
supplementation as clinically indicated. After baseline acceleromyography
recording, rocuronium 0.6mg/kg administered for intubation. Maintenance
doses of 0.1-0.2mg/kg administered based on clinical need.
When NMB was no longer required, subjects were allowed to recover to a
reappearance of T2 twitch, then reversal agents were administered IV.
Sevoflurane concentrations were maintained for a period of 10 minutes
following reversal agent administration or decreased when a TOFR 0.9 was
achieved. Any patient who did not return to a TOFR of 0.9 within 10 minutes
of reversal agent administration remained sedated, intubated, & ventilated in
the recovery room until a TOFR 0.9 was achieved for safe extubation.

Time to TOFR
of 0.9 with
Sugammadex
1.5 minutes to
recover to a
TOFR 0.9
following
administration of
sugammadex
2mg/kg

Time to TOFR of
0.9 with
Neostigmine
18.6 minutes to
recover to a TOFR
0.9 following
administration of
neostigmine
50mcg/kg +
glycopyrrolate
10mcg/kg
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ASA Class ≤
3

Postoperative clinical assessments were performed by the blinded safety
assessor.

Type of Elective Procedure
Distribution of surgical procedures:
Operations of ear, nose, & larynx (19%)
Operations of teeth, jaws, mouth, &
pharynx (16%)
Operations of digestive system & spleen
(16%)
Operations of urinary system, male genital
organs, & retroperitoneal space (13%)
Operations of musculoskeletal system
(12%)
Operations of female genital organs (9%)
Operations of endocrine system (7%)
Operations of eye & adjacent structure
(4%)
Operations of mammary gland surgery
(2%)

Adverse Events
Drug related adverse events
occurring in 1+ subjects in
either group:

Results
Treatment groups were
comparable regarding: age,
weight, & height

o Dry mouth (neostigmine =
3; sugammadex =3)
o Nausea (neostigmine =2;
sugammadex =2)
o Procedural HTN
(sugammadex = 2)
o Vomiting (sugammadex
=2)
o Albumin in urine
(neostigmine =2)

Distribution of surgical
procedures was comparable
across treatment groups

Isolated adverse events:
o Severe abdominal pain
(sugammadex = 1)
o Severe bradycardia
(neostigmine = 1)
Serious Adverse Events (not
specified):
o Sugammadex =2
o Neostigmine = 3

Maintenance doses of inspired
sevoflurance and total doses of
rocuronium were comparable
between groups
All study sites had consistent
results when comparing
sugammadex vs. neostigmine
Sugammadex was faster in
attaining a TOFR 0.9 than
neostigmine when rocuroniuminduced NMB was present
(P < 0.0001)

Limitations
Financial support
provided by Merck
Sharp & Dohme
Corp.
Doses of study
related drugs was
not specific
regarding whether
ideal body weight
or actual body
weight was used to
determine dosing
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Appendix E
Critical Appraisal Skills Programme (CASP) Tables
11 Questions
1

Did the trial address a clearly focused issue?

2

Was the assignment of patients to treatments
randomized?

3

Were all the patients who entered the trial properly
accounted for at its conclusion?
Were patients, health workers, and study personnel
‘blind’ to treatment?
Were the groups similar at the start of the trial?

4
5
6
7

Aside from the experimental interventions, were the
groups treated equally?
How large was the treatment effect?

8

How precise was the estimate of the treatment effect?

9

Can the results be applied in your context? (Or to the
local population?)
10 Were all clinically important outcomes considered?
11 Are the benefits worth the harms and costs?

(CASP, 2017)

Yes

Can’t
Tell

No
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Table E1 - Wu, X., Oerding, H., Liu, J., Vanacker, B., Yao, S., Dahl, V., … Woo, T.
(2014). Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized
study in Chinese and Caucasian subjects. BMC anesthesiology, 14(53).
doi:10.1186/1471-2253-14-53
11 Questions
1

2

3

4

5

Did the trial address a clearly focused issue? Yes, the
primary objective of this study was to evaluate the efficacy and
safety of sugammadex versus neostigmine to reverse
rocuronium-induced neuromuscular blockade in Chinese
subjects (n=230). Caucasian subjects were included with a
smaller sample size (n=59) since efficacy had been previously
established in Caucasian subjects in previous studies. A
sample of ASA I, II, III adults undergoing elective surgery with
general anesthesia were recruited.
Was the assignment of patients to treatments randomized?
Yes, subjects were randomized via a central, computergenerated randomization schedule. Subjects were randomized
in a 1:1 ratio to received either sugammadex 2mg/kg or
neostigmine 50mcg/kg with atropine 10-20mcg/kg.
Were all the patients who entered the trial properly
accounted for at its conclusion? Yes, 308 subjects were
included for randomization of treatment. 17 discontinued prior
to treatment. Of the 291 subjects who received treatment, 2
were excluded from data analysis.
Were patients, health workers, and study personnel ‘blind’
to treatment? Patients who consented to study participation,
were blinded to whether they received sugammadex or
neostigmine + atropine. Anesthesia providers administering
the medications were not blinded to the treatment in which
their patient received. Study personnel in the postoperative
period were blinded to treatment.
Were the groups similar at the start of the trial? The
groups were racially divided at the start of the study, as the
purpose of this trial was to determine efficacy in Chinese
subjects. (Since efficacy had already been established in
Caucasian subjects in previous studies.) Characteristics that
were similar across groups included: elective surgical
procedure, ASA class I, II, III, and rocuronium-induced

Yes Can’t No
Tell
ü

ü

ü

ü

ü
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neuromuscular blockade with propofol anesthesia. Gender
differences were not revealed.

6

Aside from the experimental interventions, were the groups
treated equally? Yes. Anesthesia induction and maintenance
was determined by the subject’s clinical needs. Monitoring
devices utilized were standardized across groups. There were
no gross differences noted in equality between groups.
7 How large was the treatment effect? A significantly faster
recovery to a TOFR of 0.9 was assessed in both Chinese and
Caucasian treatment groups that were given sugammadex when
compared to neostigmine. The authors estimated the time to
achieve of TOFR of 0.9 in Chinese subjects was 5.7 times
faster with sugammadex versus neostigmine (P < 0.0001). In
Caucasian subjects, the authors estimated recovery to a TOFR
of 0.9, 4.8 times faster with sugammadex versus neostigmine
(P < 0.0001)
8 How precise was the estimate of the treatment effect? The
authors determined that 115 Chinese subjects and 30 Caucasian
subjects per treatment group would have to be enrolled to give
a power of 95% and a significance level of 0.05.
9 Can the results be applied in your context? (Or to the local
population?) The patient population fits this systematic
review’s inclusion criteria. The results of this study directly
apply to the context of this systematic review.
10 Were all clinically important outcomes considered? The
outcomes to be assessed in this systematic review were present
in this study.
11 Are the benefits worth the harms and costs? The most
severe adverse events assessed in the study included
bradycardia and hypersensitivity reactions, which are potential
risks of any medication administered under general anesthesia.
The benefits of receiving the study drug outweighed the risks.

ü

ü

ü

ü

ü
ü
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Table E2 - Woo, T., Kim, K.S., Shim, Y.H., Kim, M.K., Yoon, S.M., Lim, Y,J., … Chon,
J.Y. (2013). Sugammadex versus neostigmine reversal of moderate rocuronium-induced
neuromuscular blockade in Korean patients. Korean Journal of Anesthesiology, 65(6),
501-507. https://dx.doi.org/10.4097/kjae.2013.65.6.501
11 Questions
1

2

3

4

Did the trial address a clearly focused issue? The purpose
of this study was to establish the safety and efficacy of
sugammadex versus neostigmine as the reversal agent for
rocuronium-induced neuromuscular blockade in Korean
patients. A sample of patients ASA class I, II, III, undergoing
an elective surgical procedure under general anesthesia using
rocuronium for induction and maintenance of neuromuscular
blockade were included. Subjects were of Korean descent,
born in Korea, with a current Korean home address, and never
having emigrated out of Korea.
Was the assignment of patients to treatments
randomized? Patient were randomized into 2 groups on a
1:1 basis, however the study personnel did not provide
specific information on how the randomization process was
completed.
Were all the patients who entered the trial properly
accounted for at its conclusion? A total of 128 patients
were randomized into the study. A patient disposition chart
was included to diagram the flow of subjects throughout the
study. 64 patients were allocated into each study group. 4
subjects from each group did not receive the intervention for
“administrative reasons”. 1 subject from each group was
excluded from analysis due to lacking efficacy data. Of the
final 59 subjects in each group, 2 subjects in the neostigmine
group were excluded due to “major protocol violations”.
Were patients, health workers, and study personnel
‘blind’ to treatment? Patients were blinded to the treatment
they received. The anesthesiologist administering the
randomized study drug was not blinded but was prohibited
from revealing the assigned treatment group to the safety
assessor postoperatively. Study personnel in the postoperative period were blinded to the treatment subjects
received.

Yes Can’t No
Tell
ü

ü

ü

ü
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5

Were the groups similar at the start of the trial? Korean
subjects ASA Class I, II, III, of adult age undergoing an
elective surgical procedure under general anesthesia were
included in both groups. No significant differences between
the two groups regarding patient characteristics (sex, weight,
height, race) were noted. The intention-to-treat population
was 59 in both groups. Classification of surgical procedure
was comparable between groups.
6 Aside from the experimental interventions, were the
groups treated equally? Anesthesia was induced with IV
propofol and maintained with inhalational sevoflurane, and
opioids were administered as clinically required in both
groups. Monitoring devices and rocuronium dosing was
standardized across both groups. Both groups received the
study drug at the reappearance of a T2 twitch on TOF
monitoring.
7 How large was the treatment effect? Recovery to a TOFR
of 0.9 was significantly faster following administration of
sugammadex (mean time: 1.8 minutes) versus neostigmine
(mean time: 14.8 minutes). (P < 0.0001) Statistical analysis
revealed sugammadex to be 8.1 times faster than neostigmine.
8 How precise was the estimate of the treatment effect?
Study personnel calculated a sample size of 50 subjects per
treatment group was necessary to provide a power of 95% and
a significance level of 0.05.
9 Can the results be applied in your context? (Or to the
local population?) The patient population fits this systematic
review’s inclusion criteria. The results of this study directly
apply to the context of this systematic review.
10 Were all clinically important outcomes considered? The
outcomes to be assessed in this systematic review were
present in this study.
11 Are the benefits worth the harms and costs? Adverse
events were similar between treatment groups, including
incidences of nausea and vomiting, bradycardia, and
headache. These adverse events are potential risks of any
medication administered under general anesthesia. The
benefits of this study outweigh the risks.
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Table E3 - Gaszynski, T., Szewczyk, T., & Gaszynski, W. (2011). Randomized
comparison of sugammadex and neostigmine for reversal of rocuronium-induced muscle
relaxation in morbidly obese undergoing general anaesthesia. British Journal of
Anaesthesia, 108(2), 236-239. doi: 10.1093/bja/aer330
11 Questions
1

2
3

4

5

6

Did the trial address a clearly focused issue? The study
specifically focused on the efficacy of sugammadex versus
neostigmine for reversal of rocuronium-induced
neuromuscular blockade in morbidly obese patients
undergoing elective bariatric surgery.
Was the assignment of patients to treatments
randomized? Subjects were randomized into two groups by
a process of using previously prepared envelopes.
Were all the patients who entered the trial properly
accounted for at its conclusion? 70 trial participants were
randomized into two groups. 35 subjects were allocated into
each group to receive either neostigmine or sugammadex.
Data from all 70 participants was analyzed at the conclusion
of this study.
Were patients, health workers, and study personnel
‘blind’ to treatment? Patients who consented to study
enrollment, were blinded to whether they received
sugammadex or neostigmine for reversal of rocuroniuminduced neuromuscular blockade. The anesthesia provider
administering the anesthetic was not blinded to treatment.
The postoperative study investigator was blinded to the
treatment received.
Were the groups similar at the start of the trial? Both
groups were electively proceeding with weight loss surgery
under general anesthesia. Physical characteristics of age,
weight, height, BMI, and total rocuronium administered was
similar between groups. ASA classification was not reported
(Given the surgery is elective, ASA classifications I, II, III,
IV would be included). Both groups had an equal sample size
of 35 participants.
Aside from the experimental interventions, were the
groups treated equally? Anesthesia was induced and
maintained similarly, and standard monitoring was consistent
between groups. At the appearance of a T2 twitch, study
medications were administered according to the
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randomization process and the time to achieve a TOFR of 0.9
was measured.
7 How large was the treatment effect? Time to TOFR of 0.9
for patients who received sugammadex was 2 minutes 44
seconds (mean time=2.7 minutes). Time to TOFR of 0.9 for
patients who received neostigmine was 9 minutes (mean time
= 9.6 minutes). Mean time to achieve a TOFR of 0.9 was 3.5
times shorter in the sugammadex group (P <0.05). Of note,
the TOFR was 0.9 by the time the patient arrived in the
PACU for every case that received sugammadex.
8 How precise was the estimate of the treatment effect?
Statistical analysis was performed using a Microsoft Excel
workbook. The authors did not clearly identify the sample
size needed to provide a power analysis. Additionally, the
authors do not report a power analysis. A significance level
of 0.05 was calculated.
9 Can the results be applied in your context? (Or to the
local population?) Yes, the results of this study can be
applied to the context of this systematic review. The patient
population fits this systematic review’s inclusion criteria.
10 Were all clinically important outcomes considered? The
outcomes to be assessed in this systematic review were
present in this study.
11 Are the benefits worth the harms and costs? Two patients
who received sugammadex reported a strange taste in their
mouths, no other side effects from sugammadex were
reported. Three patients who received neostigmine were
observed to be bradycardic. No further side effects from
neostigmine were reported. The benefits of this study
outweigh the risks.
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Table E4 - Illman, H.L., Laurila, P., Antila, H., Meretoja, O., Alahuhta, S., & Olkkola, K.
T. (2011). The duration of residual neuromuscular block after administration of
neostigmine or sugammadex at two visible twitches during train-of-four monitoring.
Anesthesia & Analgesia, 112(1), 63-68. doi: 10.1213/ANE.0b013e3181fdf889
11 Questions
1

2

3

4

5

6

Did the trial address a clearly focused issue? Yes, the main
objective of this study was to determine the time gap between
the T2 twitch to the return of a TOFR of 0.9 when either
neostigmine or sugammadex was administered for reversal of
rocuronium-induced neuromuscular blockade.
Was the assignment of patients to treatments randomized?
Anesthetized patients were randomized to receive either
sugammadex or neostigmine at the conclusion of their surgical
procedure. Randomization was achieved by using computergenerated sealed envelopes. The envelope contained written
instructions to prepare either neostigmine or sugammadex.
Were all the patients who entered the trial properly
accounted for at its conclusion? All 50 patients who
enrolled in the study were accounted for at conclusion. 25
patients were allocated into each group to receive either
neostigmine or sugammadex. Data from 2 patients who
received neostigmine and 1 patient who received sugammadex
was excluded for technical failure of equipment and
awakening from anesthesia before a TOFR of 0.9 was
established. Therefore, data from 47 patients was resulted.
Were patients, health workers, and study personnel ‘blind’
to treatment? Patients who consented to study enrollment
were blinded to which treatment they received. The anesthesia
provider was blinded to treatment, as the study drug was
prepared and administered by the study nurse. The study
investigators were blinded to treatment.
Were the groups similar at the start of the trial? Both
groups were comprised of men and women aged 18-70 years
undergoing elective surgical procedures with ASA
classifications I, II, III, IV. No significant differences between
the groups based on gender, age, body mass index, or ASA
classification was detected.
Aside from the experimental interventions, were the
groups treated equally? All patients received general
anesthesia. Anesthesia induction and maintenance was
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maintained with a volatile agent and opioids. Standard
monitoring devices were utilized. Both groups received the
study drug at the reappearance of a T2 twitch on TOF
monitoring.
7 How large was the treatment effect? Patients who received
sugammadex recovered to a TOFR of 0.9 significantly faster
than patients who received neostigmine. Return to a TOFR of
0.9 in neostigmine group: 10.3 ± 5.5 minutes. Return to a
TOFR of 0.9 in sugammadex group: 0.3 ± 0.3 minutes.
(P<0.0001)
8 How precise was the estimate of the treatment effect? The
authors calculated a sample size of 23 patients in each group
would be required to demonstrate a significance level of 0.05
and power of 90%. A total of 50 patients were enrolled. 23
patients received neostigmine and 24 patients received
sugammadex. The authors determined there was a statistical
significance in patients who received sugammadex versus
neostigmine (P <0.0001)
9 Can the results be applied in your context? (Or to the local
population?) Yes, the results of this study can be applied to
the context of this systematic review. The patient population
fits this systematic review’s inclusion criteria.
10 Were all clinically important outcomes considered? A
TOFR of 0.9 was calculated for all patients enrolled in this
study. The outcomes to be assessed in this systematic review
were present in this study.
11 Are the benefits worth the harms and costs? One patient
who received neostigmine reported postoperative nausea. No
other adverse events were reported. The benefits outweigh the
harms and costs.
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Table E5 - Blobner, M., Eriksson, L.I., Scholz, J., Motsch, J., Rocca, G.D., & Prins, M.E.
(2010). Reversal of rocuronium-induced neuromuscular blockade with sugammadex
compared with neostigmine during sevoflurane anaesthesia: Results of a randomized
controlled trial. European Journal of Anaesthesiology, 27(10). doi:
10.1097/EJA.0b013e32833d56b7
11 Questions
1

2

3

4

5

6

Did the trial address a clearly focused issue? Yes, this
study evaluated whether reversal of rocuronium-induced
neuromuscular blockade using sugammadex is faster than
reversal using neostigmine.
Was the assignment of patients to treatments
randomized? Randomization was achieved by assigning
codes via a central-randomization system. Patients were
given a number in order by which they enrolled in the study,
and a treatment code was assigned using the randomization
system.
Were all the patients who entered the trial properly
accounted for at its conclusion? All 98 patients who
enrolled in the study were accounted for at conclusion. 49
patients were allocated into each group to receive either
neostigmine or sugammadex. Data from 1 patient in each
group was excluded as the patient’s did not receive the study
drug.
Were patients, health workers, and study personnel
‘blind’ to treatment? Patients were blinded to treatment.
The anesthetist was not blinded to the drug administered.
Postoperatively, study personnel were blinded to treatment.
Were the groups similar at the start of the trial? All
patients were scheduled for an elective surgical procedure, at
least 18 years of age and ASA class I-III. Treatment groups
were mostly comparable in terms of their baseline
characteristics (age, weight, and height). The relative
distribution of surgical procedures was similar across the
two groups.
Aside from the experimental interventions, were the
groups treated equally? All patients received general
anesthesia. Anesthesia induction and maintenance was
comparable between the two groups. Standard monitoring
devices were utilized. Both groups received the study drug
at the reappearance of a T2 twitch on TOF monitoring.
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7

How large was the treatment effect? Patients who
received sugammadex recovered to a TOFR of 0.9 in a
geometric mean time of 1.5 minutes. Patients who received
neostigmine recovered to a TOFR of 0.9 in a geometric
mean time of 18.6 minutes. Within 5 minutes of receiving
reversal agents, 98% of sugammadex patients, and 11% of
neostigmine patients, recovered to a TOFR of 0.9. The
authors calculated a statistically significant difference in
patients who received sugammadex versus neostigmine
(P<0.0001)
8 How precise was the estimate of the treatment effect? It
was determined by the authors a sample size of 46 patients
in each group would be necessary to demonstrate a power of
95% and significance level of 0.05.
9 Can the results be applied in your context? (Or to the
local population?) The patient population fits this
systematic review’s inclusion criteria. The results of this
study directly apply to the context of this systematic review.
10 Were all clinically important outcomes considered? Time
to recovery of a TOFR of 0.9 was a clinically important
outcome assessed in this study. Therefore, the outcomes to
be assessed in this systematic review were present in this
study.
11 Are the benefits worth the harms and costs? At least one
adverse event was reported in 84 of the study participants.
Adverse events included: dry mouth, nausea, procedural
hypotension, and vomiting. Adverse events are potential
risks of any medication administered under general
anesthesia. The benefits outweigh the harms and costs.

ü

ü

ü

ü

ü

68
Appendix F
Cross Study Analysis
Author

Time to TOFR of
0.9 with
Sugammadex

Time to TOFR of
0.9 with
Neostigmine

Type of Surgical
Procedure

Wu et al., 2014

1.6 minutes in
Chinese subjects

9.1 minutes in
Chinese subjects

Not Specified

1.4 minutes in
Caucasian subjects

6.7 minutes in
Caucasian subjects

1.8 minutes

14.8 minutes

Woo et al., 2013

Operations of the ear,
nose, & larynx (48%)
Operations of female
genital organs (18%)
Operations of digestive
system & spleen (17%)

2 minutes 44
seconds

9 minutes

Elective bariatric surgery

Illman et al., 2011

1.7 ± 0.7 minutes

13.3 ± 5.7 minutes

Not Specified

Blobner et al., 2010

1.5 minutes

18.6 minutes

Operations of ear, nose, &
larynx (19%)

Gaszynski et al.,
2011

Operations of teeth, jaws,
mouth, & pharynx (16%)
Operations of digestive
system & spleen (16%)
Operations of urinary
system, male genital
organs, & retroperitoneal
space (13%)
Operations of
musculoskeletal system

69
(12%)
Operations of female
genital organs (9%)
Operations of endocrine
system (7%)
Operations of eye &
adjacent structure (4%)
Operations of mammary
gland surgery (2%)

